• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Nutraceuticals
    • Markets
    • Health
    • Jobs
    • Events
    • Buyers' Guide
    • Showcases
    • More
  • Magazine
  • News
  • Exclusives
  • Nutraceuticals
  • Markets
  • Health
  • Jobs
  • Events
  • Buyers' Guide
  • Showcases
  • Current & Past Issues
    Features
    Columns
    Editorials
    Digital Edition
    Subscribe Now
    Advertise Now
    eNewsletter
    Editorial Guidelines
    Top Features
    Health Products Association - China Executive Director Reflects on Market Dynamics, Challenges

    Blood Sugar Management: Personalized Testing Drives Home The Need for Early Intervention

    New and Evolving Formulation Options Must Be Mindful of Blood Sugar Maintenance

    Tapping Functional Beverages to Meet Modern Wellness Needs

    Adaptogens: Where Ancient Remedies Meet Modern Wellness Products
    Breaking News
    Certifications, Approvals and Patents
    Exclusives
    Industry & Market News
    People
    Products
    Regulatory
    Research
    Supplier News
    Supplier Insights
    Live From Shows
    Top News
    CRN Announces New Staff Appointments

    Food Supplements Europe: Most Consumers Use Dietary Supplements Safely

    True Westfjords Launches Dropi Cod Liver Oil Tonic

    Alkemist Labs Warns About Missing Components to Pesticide Testing

    Boswellia and Bengal Quince Fruit Extract Blend Linked to Respiratory Benefits
    Exclusives
    Blogs & Guest Articles
    Health E-Insights
    Area Code 420
    eBook
    Antioxidants
    Dairy-Based Ingredients
    Enzymes
    Fatty Acids
    Fiber & Carbohydrates
    Green Foods
    Herbs & Botanicals
    Marine Nutraceuticals
    Minerals
    Omega 3s
    Probiotics & Prebiotics
    Proteins, Peptides, Amino Acids
    Sweeteners
    Vitamins

    True Westfjords Launches Dropi Cod Liver Oil Tonic

    Alkemist Labs Warns About Missing Components to Pesticide Testing

    Boswellia and Bengal Quince Fruit Extract Blend Linked to Respiratory Benefits

    Largest Cannabinoids Trial to Date Yields Positive Findings on Pain Management

    Kensing Acquires Vitae Naturals
    Consumer Trends
    Contract Manufacturing
    Cosmeceuticals / Nutricosmetics
    Delivery & Dosage Technologies
    Dietary Supplements
    Flavors & Colors
    Functional Foods & Beverages
    Healthcare Trends
    Medical Nutrition
    Mergers & Acquisitions
    Natural/Organic
    Nutrition Bars
    Packaging
    Pet Nutraceuticals
    Quality & Safety
    Regulations
    Research
    Testing
    World Markets

    CRN Announces New Staff Appointments

    Food Supplements Europe: Most Consumers Use Dietary Supplements Safely

    True Westfjords Launches Dropi Cod Liver Oil Tonic

    ODSP Director Cara Welch Discusses Agency Priorities

    Alkemist Labs Warns About Missing Components to Pesticide Testing
    Bone & Joint Health
    Cancer Risk
    Cardiovascular Health
    Cognitive Function
    Diabetes & Blood Sugar Management
    Digestive Health
    Energy
    Eye Health
    Healthy Aging
    Immune Function
    Infant & Children's Health
    Inflammation
    Men's Health
    Mood Health & Sleep
    Oral Health
    Sexual & Reproductive Health
    Skin Health
    Sports Nutrition
    Weight Management/Weight Loss
    Women's Health

    Boswellia and Bengal Quince Fruit Extract Blend Linked to Respiratory Benefits

    Younger Consumers Drive Growing Demand for Ingestible Beauty and Skin Care Products

    Lynside® Forte B offers full range of B-vitamin benefits with nutritional yeast

    CoQ10 and Royal Jelly Supplementation May Improve High Intensity Exercise

    Shiitake Mushroom Extract Appears Helpful in HPV Infections
    Industry Events
    Live From Show Events
    Webinars
    All Companies
    Categories
    Trade Associations
    Company Capabilities
    International Buyers Guide Companies
    Atlantia Clinical Trials

    Verdure Sciences

    Bioactive Resources

    Nutrition21, LLC

    Bioenergy Life Science, Inc. (BLS)
    Companies
    Product Releases
    News Releases
    Literature / Brochures
    White Papers
    Jobs
    VIdeos
    Services
    Add New Company
    International Buyers Guide Companies
    Atlantia Clinical Trials

    Verdure Sciences

    Bioactive Resources

    Nutrition21, LLC

    Bioenergy Life Science, Inc. (BLS)
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • All Companies
      • Categories
      • Trade Associations
      • Company Capabilities
    • Nutraceuticals
      • Antioxidants
      • Dairy-Based Ingredients
      • Enzymes
      • Fatty Acids
      • Fiber & Carbohydrates
      • Green Foods
      • Herbs & Botanicals
      • Marine Nutraceuticals
      • Minerals
      • Omega 3s
      • Probiotics & Prebiotics
      • Proteins, Peptides, Amino Acids
      • Sweeteners
      • Vitamins
    • Markets
      • Consumer Trends
      • Contract Manufacturing
      • Cosmeceuticals / Nutricosmetics
      • Delivery & Dosage Technologies
      • Dietary Supplements
      • Flavors & Colors
      • Functional Foods & Beverages
      • Healthcare Trends
      • Medical Nutrition
      • Mergers & Acquisitions
      • Natural/Organic
      • Nutrition Bars
      • Packaging
      • Pet Nutraceuticals
      • Quality & Safety
      • Regulations
      • Research
      • Testing
      • World Markets
    • Health
      • Bone & Joint Health
      • Cancer Risk
      • Cardiovascular Health
      • Cognitive Function
      • Diabetes & Blood Sugar Management
      • Digestive Health
      • Energy
      • Eye Health
      • Healthy Aging
      • Immune Function
      • Infant & Children's Health
      • Inflammation
      • Men's Health
      • Mood Health & Sleep
      • Oral Health
      • Sexual & Reproductive Health
      • Skin Health
      • Sports Nutrition
      • Weight Management/Weight Loss
      • Women's Health
    • Online Exclusives
    • Webinars
    • Slideshows
    • Blogs & Guest Articles
    • Health E-Insights
    • Videos
    • Podcasts
    • Infographics
    • eBook
    • Whitepapers
    • Research
      • TrendSense
      • Monograph Center
      • White Papers
      • Research News
    • Jobs
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Supplier Showcases
      • Companies
      • Product Releases
      • News Releases
      • Literature / Brochures
      • White Papers
      • Jobs
      • VIdeos
      • Services
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    NAC Supplements Could be Banned Unless FDA Reverses Course

    Warning letters from July 2020 have set off a firestorm, and the stakes are high for medical professionals, patients, and nutraceutical companies.

    NAC Supplements Could be Banned Unless FDA Reverses Course
    Related CONTENT
    • ODSP Director Cara Welch Discusses Agency Priorities
    • Lynside® Forte B offers full range of B-vitamin benefits with nutritional yeast
    • EIRICH Machines
    • FSA: Three-Quarters of U.K. Citizens Are Concerned about the Cost of Food
    • Sen. Markey Introduces Bill Calling for Stricter GRAS Framework
    By Erik Goldman, Holistic Primary Care03.02.22
    Americans could lose access to dietary supplements containing N-acetyl cysteine (NAC) in 2022, unless the industry can convince the Food and Drug Administration (FDA) that this glutathione precursor was widely used as a supplement or a food ingredient prior to the mid-1990s.

    FDA contends that because NAC was approved in 1963 as an inhaled drug for obstructive lung disease (Mucomyst), and then again in 1985 as an oral agent to treat acetaminophen toxicity (Acetadote), it is by definition excluded from the dietary supplement category. That’s despite the fact that NAC supplements have been on the market for more than 30 years.

    [Update: FDA Issues NAC Enforcement Discretion Guidance]

    In a concerted effort to protect NAC supplements, individual companies as well as industry trade groups and some practitioner organizations have put considerable effort into making a case that this compound should be grandfathered as an “old” (i.e., pre-DSHEA [Dietary Supplement Health and Education Act] dietary ingredient.

    The industry’s position, expressed via comments on an FDA docket, is that NAC is extremely safe, that it has been used in supplements well before DSHEA was passed, and that a retroactive application of a drug exclusion provision based on obsolete patents constitutes an unfair restriction of trade.

    If you haven’t been following the NAC saga, here’s a quick recap:

    In July 2020, the FDA issued a flurry of warning letters to several companies marketing NAC as a hangover remedy, stating that these companies were making unlawful claims and illegally selling a pharmaceutical ingredient mislabeled as a supplement. 

    The warning letters contained language stating that: “FDA has concluded that NAC products are excluded from the dietary supplement definition under section 201(ff)(3)(B)(i) of the Act [21 U.S.C. § 321(ff)(3)(B)(i)]. Under this provision, if an article (such as NAC) has been approved as a new drug under section 505 of the Act [21 U.S.C. § 355], then products containing that article are outside the definition of a dietary supplement, unless before such approval that article was marketed as a dietary supplement or as a food. NAC was approved as a new drug under section 505 of the Act [21 U.S.C. § 355] on September 14, 1963. FDA is not aware of any evidence that NAC was marketed as a dietary supplement or as a food prior to that date.”

    In other words, the agency reverted to a position that NAC is a pharmaceutical ingredient based on a 60-year-old approval for an inhaled drug that was discontinued long ago.

    In these warning letters, the FDA invoked the Drug Exclusion Provision within the Food, Drug, and Cosmetic Act, which states that a dietary supplement cannot contain:

    • an article approved as a new drug; or
    • an article authorized for investigation as a new drug, antibiotic, or biological for which substantial clinical investigations have been instituted, and for which the existence of such investigations has been made public, which was not before such approval, certification, licensing, or authorization marketed as a dietary supplement or as a food, unless the Secretary, in the Secretary’s discretion, has issued a regulation, after notice and comment, finding that the article would be lawful under this chapter.
    This was despite the fact that FDA has tacitly permitted the sale of NAC supplements for many years. There are well over 1,100 non-Rx NAC products on the market, typically sold for liver health, detoxification, antioxidant activity, and immune system support. The ingredient is very safe, and until the June 2020 warning letters, the FDA had no issues with it.

    Ripple Effects
    On their own, these warnings would have had little impact; the companies targeted are not major players, and the claims that NAC can prevent or cure hangovers are indeed questionable. The agency did not issue letters to companies selling NAC for other health purposes, and it has not taken any further action to ban all NAC supplements. Not yet, anyway.

    But in May 2021, Amazon announced that it was eliminating all NAC-containing supplements from its digital shelves, citing the FDA’s new position that these are basically unlawful drugs. Amazon’s move greatly amplified the impact of the FDA’s move, given that the e-commerce titan accounts for between 40% and 60% of total sales for many supplement brands.

    Though the FDA has not officially banned NAC supplements, the new position—and especially Amazon’s response to it—has definitely blunted sales.

    According to Larisa Pavlick, vice president of global regulatory and compliance at the United Natural Products Alliance (UNPA), there were 718 NAC-containing products available on Amazon at the end of 2020; one year later, at the end of 2021, all of them were gone. For all intents and purposes, it is no longer possible to buy NAC on Amazon anymore. 

    All Hands On Deck
    In November 2021, just before Thanksgiving, FDA issued a request for information on the past use of NAC in supplements, including any and all relevant safety data. Specifically, FDA called for: “information on the earliest date that NAC was marketed as a dietary supplement or a food, the safe use of NAC in products marketed in dietary supplements, and any safety concerns.”

    If the industry is able to prove NAC was broadly used in supplements prior to DSHEA in 1994, the substance would qualify as an “old dietary ingredient,” and be exempted from the prior drug exclusion.

    Calling it an “all-hands-on-deck situation,” Pavlick and UNPA quickly coordinated with the Council for Responsible Nutrition, the American Herbal Products Association, and a long list of concerned stakeholders to gather information to support the exemption.

    Because DSHEA became law in 1994, in the pre-internet era, much of the needed documentation is in paper form—old nutrition catalogs, manufacturing spec sheets, lab testing data, ancient freight bills indicating interstate commerce, product labels (if they have expiration dates). 

    UNPA assembled an NAC working group that dug up and sorted through “warehouses, boxes, and basements for old paper records, and through antiquated software systems to provide a significant collection of pre-DSHEA records,” said UNPA President Loren Israelsen.

    The UNPA team also audited back issues of the Townsend Letter, a print magazine that has covered the field of “alternative” medicine since the 1980s. The audit turned up 13 ads for non-prescription products containing NAC from the pre-DSHEA era. Companies producing NAC supplements prior to 1994 include: Allergy Research Group, Pure Encapsulations, NF Formulations, Tyler Encapsulations, and Thorne Research.

    The American Association of Naturopathic Physicians (AANP), representing the nation’s NDs and NMDs, joined the effort to rescue NAC from regulatory exile. Naturopaths and other holistic physicians routinely recommend NAC for their patients who need antioxidant and detox support. Many are also using it in their “Long COVID” support protocols.

    In its comments to the FDA, AANP noted that safety studies of oral NAC and citations about it in the naturopathic literature date back to the early 1970s. Based on 126 responses to a member survey, the organization holds that naturopaths have been routinely using NAC in practice since at least 1990. AANP provided the FDA with many verbatim comments from practitioners describing the utility and safety of the ingredient, and their own lengthy clinical experience with it.

    “Until recently, FDA has consistently and affirmatively permitted manufacturers to market products with NAC. The impact of the FDA’s Warning Letters has been to restrict patient access to NAC—a critical nutritional supplement—which negatively affects the health of patients,” AANP contended in its docket comments. “We urgently request that the FDA exercise its authority to reverse this policy change and again allow manufacturers to market dietary supplements containing NAC as has been safely done for over 40 years.”

    According to Israelsen, “Our new evidence for pre-DSHEA dietary supplement usage is substantial. We have provided solid documentation for NAC as a pre-DSHEA ingredient and for finished dietary supplement products on the market prior to October 15, 1994.”

    Whether FDA agrees with this assessment remains to be seen.

    Petitions and Lawsuits
    Many of the stakeholders who commented on the docket provided evidence of NAC’s safety. Indeed, there are many studies of NAC supplementation for diverse clinical problems in a wide range of patient subgroups showing very few adverse events.

    FDA did ask for safety data, and it is important to formally establish the ingredient’s sterling track-record on the safety front. 

    But the safety of NAC was never really in question. Neither the 2020 warning letters nor Amazon’s purge policy cite adverse events as a reason for action. The real issue is whether the 1963 approval of inhaled NAC as a drug can be retroactively applied in 2022 to block further sale of NAC in oral supplement forms.

    Last June, the Council for Responsible Nutrition filed a Citizen Petition urging the FDA to reverse its stance, and to “revert to its longstanding policy of allowing manufacturers to market products containing NAC as dietary supplements” without obstruction. 

    CRN’s leaders had several meetings with the FDA since the 2020 warning letters, and claimed that the agency “is considering CRN’s position.” But the regulators have given no deadline for resolution of the issue.

    The Natural Products Association (NPA) followed suit with a similar Citizen Petition in August; and last December it went a step further and filed a lawsuit against the FDA in the U.S. District Court in Maryland, seeking a permanent injunction against the FDA’s retroactive exclusion of NAC from the definition of dietary supplements.

    NPA claims FDA acted unlawfully in its application of the Prior Drug Exclusion standard, calling it, “a reckless misuse of government resources” and “a regulatory sneak-attack.”

    The complaint states that, “NPA’s members have suffered harm as a direct and proximate result of FDA’s recent final agency actions concluding that the drug exclusion provision of DSHEA applies retroactively to NAC.

    NPA members who have been selling NAC for years, if not decades, have seen their sales dry up as result of having to preemptively pull products from the shelves by virtue of FDA’s unlawful decisions.”

    It also points out that FDA has been denying export certificates for NAC supplements, precluding U.S. distributors from marketing these products overseas.

    If NPA wins its case, the injunction would block FDA from taking regulatory action against manufacturers, distributors, or retailers of NAC-based supplements solely on the ground that the ingredient is a pharmaceutical. But that’s a big “If.”

    There’s a note of irony in the suit, given that NPA’s CEO, Daniel Fabricant, PhD, was Director of the FDA’s Division of Dietary Supplement Programs from 2011 to 2014.

    Fabricant contends that his former employer is way out of line on this issue. “This is government regulation run amok,” he said in a press release.

    Though it is a rare occurrence, this is not the first time FDA has invoked the prior drug exclusion provision to retroactively regulate supplement ingredients. Over the years, it took similar action—to varying degrees of success—against vinpocetine, red yeast rice, vitamin B6 (pyridoxamine), and CBD.

    Industry leaders are concerned that FDA’s position on NAC sets the stage for a wave of actions to eliminate other supplement ingredients such as L-carnitine, niacin, and CBD, which are currently available in supplement as well as prescription pharmaceutical form. Several herbs currently sold as supplements are also the sources of prescription drugs. They’re at risk too.

    The contention over NAC clearly has implications that extend far beyond this one isolated compound.

    NPA’s lawsuit also says the matter is exacerbating labor shortages and employee conflicts at a time when many companies are already struggling.

    In addition to the NAC lawsuit, NPA filed two petitions with the U.S. Court of Appeals on Nov. 11, 2021 and Dec. 7, 2021 arguing the Biden Administration’s vaccine and testing mandate for businesses was unconstitutional, preempted state laws, and would negatively impact the ability of businesses to meet demand for natural products by slowing delivery times and driving-up costs. The issue subsequently went to the Supreme Court, which blocked the vaccine mandate for businesses in January. 

    People familiar with the subject say it is likely the District Court will dismiss the NAC complaint on the grounds that FDA has not taken any definitive action—such as a ban—against NAC, but merely issued warning letters to a handful of companies. These letters do not constitute “final actions.”

    But the NAC issue has drawn the attention of some legislators. In October, Rep. Jeff Duncan (R-SC) sent a letter to the FDA demanding that regulators clarify their position on NAC, and cite any adverse events or other safety concerns that would warrant action to restrict sales. Earlier, Sen. Mike Lee (R-UT) had called on the FDA to hold a public hearing on the NAC issue, a request that so far, the FDA has denied.

    Possible Motives and Outcomes
    The reasons for FDA’s action against NAC are unclear. If the concern was merely about fringe players marketing bogus hangover cures, then warning letters about false claims should have been sufficient chastisement.

    Why invoke the prior drug exclusion?

    Some within the natural products industry believe that in targeting NAC supplements, the agency is doing the bidding of pharmaceutical companies.

    There are now 19 clinical studies of NAC for COVID-19 care in the government’s Clinical Trials registry, including several looking at NAC-based drugs. This includes a high-profile study now underway at Memorial Sloan Kettering Cancer Center involving 84 high-risk patients with COVID-19, treated with inhaled or intravenous pharmaceutical forms of NAC. This trial is slated for completion in May 2023.

    Last year, a company called Orpheris—a division of Ashvattha Therapeutics—ran a phase 1 open-label clinical study of subcutaneous injections of “OP-101,” a Dendrimer N-acetyl cysteine. The company’s long-term vision for OP-101 is to develop it as a drug for childhood cerebral adrenoleukodystrophy (ccALD). Further, the company plans to “investigate the potential of OP-101 in other neurological diseases,” particularly Parkinson’s and amyotrophic lateral sclerosis (ALS).

    One comment filed with the FDA on the NAC docket does indicate that pharma players see prior drug exclusion as a viable strategy for clearing the field of supplement competition.

    John Gold, PhD, vice president of Emmeria, a privately-held drug company, writes that his company is “the sole sources of EMM-737, EMM-738, EMM-739 and EMM-740,” Emmeria’s proprietary form of trimethylglycine, astragaloside, ellagic acid and berberine, which have been studied as new drugs and for which substantial clinical investigations have been instituted. “As a company that has instituted clinical studies on trimethylglycine, astragaloside, ellagic acid, and berberine, we request that FDA take the preclusion provision of Section 201(ff) of the Federal, Food, Drug, and Cosmetic Act seriously to protect the right of companies that have spent significant time and research to develop drugs products from competition from dietary supplements that are clearly new dietary ingredients that have never filed a new dietary ingredient notification prior to the institution of substantial clinical trials.”

    The supplement industry trade groups, along with the AANP, have amassed convincing evidence that NAC was widely used in supplement form well before 1994, and therefore prior to the formal definition of the term “dietary supplement” and to the prior drug exclusion provision.

    But this forces the FDA into a difficult decision: either formally designate NAC as a drug, and ban its use in supplements outright, or fall back to the prior status quo and permit unrestricted sale of NAC products so long as marketing claims are valid and stay within the language of structure/function rather than disease treatment or prevention.

    If the agency takes the hardline stance, it will be rightly criticized for unnecessarily banning a harmless, effective, and accessible self-care modality in the middle of a raging pandemic, for no discernable reason and in the absence of any evidence of harm.

    If FDA backtracks and reverts to permitting the unrestricted sale of NAC in oral supplements despite previously stating that NAC is a drug, it risks looking weak and indecisive. It also dissipates the future power of the “prior drug exclusion” clause.

    After more than a year without a leader, FDA now has a new commissioner following the Feb. 15 confirmation of Robert Califf, MD. Over the course of his career, Califf has said surprisingly little about dietary supplements, so his overall attitude toward them is not yet known.

    Whether Califf’s presence at FDA will shift the agency’s position on NAC—and if so, in what direction—also remains to be seen. 

    Holistic medical professionals, their patients, and the nutraceutical companies that serve them have much to lose—or to gain—in the outcome of this contentious situation.


    Erik Goldman is co-founder and editor of Holistic Primary Care: News for Health & Healing, a quarterly medical publication reaching about 60,000 physicians and other healthcare professionals nationwide. He is also co-producer of the Practitioner Channel Forum, the nation’s leading conference focused on opportunities and challenges in the practitioner segment of the dietary supplement industry. 
    Related Searches
    • Proteins, Peptides, Amino Acids
    • Regulations
    • Dietary Supplements
    Related Knowledge Center
    • Proteins, Peptides, Amino Acids
    • Dietary Supplements
    • Regulations
    Suggested For You
    ODSP Director Cara Welch Discusses Agency Priorities ODSP Director Cara Welch Discusses Agency Priorities
    Lynside® Forte B offers full range of B-vitamin benefits with nutritional yeast Lynside® Forte B offers full range of B-vitamin benefits with nutritional yeast
    EIRICH Machines EIRICH Machines
    FSA: Three-Quarters of U.K. Citizens Are Concerned about the Cost of Food FSA: Three-Quarters of U.K. Citizens Are Concerned about the Cost of Food
    Sen. Markey Introduces Bill Calling for Stricter GRAS Framework Sen. Markey Introduces Bill Calling for Stricter GRAS Framework
    New and Evolving Formulation Options Must Be Mindful of Blood Sugar Maintenance New and Evolving Formulation Options Must Be Mindful of Blood Sugar Maintenance
    What People Were Reading in May 2022 on NutraceuticalsWorld.com What People Were Reading in May 2022 on NutraceuticalsWorld.com
    FDA Issues Draft Guidance on NDI Enforcement Discretion FDA Issues Draft Guidance on NDI Enforcement Discretion
    Supplement Formulations That Win In Wellness Supplement Formulations That Win In Wellness
    Vitamin Angels’ Mother’s Day Donation Campaign Raises Awareness for Maternal and Child Nutrition Vitamin Angels’ Mother’s Day Donation Campaign Raises Awareness for Maternal and Child Nutrition
    FDA Issues Warning Letters to Companies Selling CBD, Delta-8 THC Products FDA Issues Warning Letters to Companies Selling CBD, Delta-8 THC Products
    GC Rieber VivoMega Announces Construction of New Facility GC Rieber VivoMega Announces Construction of New Facility
    NPA Letter Spells Out Perceived Failings of Proposed Dietary Supplement Listing Act NPA Letter Spells Out Perceived Failings of Proposed Dietary Supplement Listing Act
    Undenatured Type II Collagen Ingredient Backed by Study for Joint Health Benefits Undenatured Type II Collagen Ingredient Backed by Study for Joint Health Benefits
    Nutrilead’s BeniCaros Ingredient Receives FDA Green Light  Nutrilead’s BeniCaros Ingredient Receives FDA Green Light

    Related Online Exclusives

    • Breaking News | Dietary Supplements | Industry & Market News | Quality & Safety | Regulations
      ODSP Director Cara Welch Discusses Agency Priorities

      ODSP Director Cara Welch Discusses Agency Priorities

      Facility inspections, NDIs, enforcement, and education are all top-of-mind.
      Mike Montemarano, Associate Editor 07.05.22

    • Cardiovascular Health | Cognitive Function | Dietary Supplements | Eye Health | Immune Function | Sports Nutrition | Vitamins
      Lynside® Forte B offers full range of B-vitamin benefits with nutritional yeast

      Lynside® Forte B offers full range of B-vitamin benefits with nutritional yeast

      All-in-one formula ready to be used alone or combined with other nutrients for various health applications.

    • EIRICH Machines

      EIRICH Machines

      ...
      06.22.22


    • Breaking News | Consumer Trends | Industry & Market News | World Markets
      FSA: Three-Quarters of U.K. Citizens Are Concerned about the Cost of Food

      FSA: Three-Quarters of U.K. Citizens Are Concerned about the Cost of Food

      The U.K.’s chief regulatory agency for the food industry said it plans to look at regulatory options to support food banks and government initiatives.
      06.20.22

    • Breaking News | Regulations | Regulatory News
      Sen. Markey Introduces Bill Calling for Stricter GRAS Framework

      Sen. Markey Introduces Bill Calling for Stricter GRAS Framework

      The new bill would direct the U.S. Food and Drug Administration with creating an office that would reassess whether current GRAS substances are safe.
      06.06.22

    Loading, Please Wait..
    Trending
    • High Blood DHA Levels Linked To 49% Reduced Risk Of Alzheimer’s
    • Three Grams Of Omega-3s May Be Optimal Dose For Reducing Blood Pressure
    • CoQ10 And Royal Jelly Supplementation May Improve High Intensity Exercise
    • Oregon Files Lawsuit Against GNC
    • First Day Life Shuts Down Children's Behavioral, Cognitive Health Claims Following Challenge
    Breaking News
    • CRN Announces New Staff Appointments
    • Food Supplements Europe: Most Consumers Use Dietary Supplements Safely
    • True Westfjords Launches Dropi Cod Liver Oil Tonic
    • Alkemist Labs Warns About Missing Components to Pesticide Testing
    • Boswellia and Bengal Quince Fruit Extract Blend Linked to Respiratory Benefits
    View Breaking News >
    CURRENT ISSUE

    June 2022

    • Tapping Functional Beverages to Meet Modern Wellness Needs
    • Adaptogens: Where Ancient Remedies Meet Modern Wellness Products
    • New and Evolving Formulation Options Must Be Mindful of Blood Sugar Maintenance
    • Health Products Association - China Executive Director Reflects on Market Dynamics, Challenges
    • Blood Sugar Management: Personalized Testing Drives Home The Need for Early Intervention
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    CRN Announces New Staff Appointments
    Food Supplements Europe: Most Consumers Use Dietary Supplements Safely
    True Westfjords Launches Dropi Cod Liver Oil Tonic
    Coatings World

    Latest Breaking News From Coatings World

    Advanced Polymer Coatings Inks Ten Tanker deal with Turkey’s Chemfleet
    Heubach Launches Expanded Colanyl 500 range for Vibrant Orange Colors
    The ChemQuest Group Launches New Website
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Getinge Completes Purchase of Fluoptics SAS
    InBody Expands Blood Pressure Line
    Royal Philips Teams Up with Biodesix
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Evotec, Boehringer Ingelheim and BioMérieux Form Joint Venture
    Qualigen, Hande Sciences Partner to Scale-Up Mfg. for IND-Enabling Studies
    KBI Biopharma, Selexis Open State-of-the-Art Facility in Geneva
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Summer Camp Launches Line of Safe & Effective Sun Care Products
    Ameripen’s Dan Felton Voices Concerns About California Senate Bill 54
    Arkay Receives Platinum Rating in EcoVadis CSR Assessment
    Happi

    Latest Breaking News From Happi

    Azelis Signs Distribution Agreement with Seqens Advanced Cosmetics
    Talc-Free Eyeshadow Debuts from Kevyn Aucoin Beauty
    Jojoba Desert Achieves EcoVadis Gold Medal
    Ink World

    Latest Breaking News From Ink World

    Two ProAmpac Facilities Receive Key ISO Certifications
    BASF Venture Capital Invests in Climentum Capital’s First Fund
    JNS-SmithChem Acquires Tampa-Based Gulf Coast Chemical
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Paper Resources rebrands as Pri+
    Rotocon debuts new logo
    Mark Andy to showcase digital transformation at Labelexpo ​​​​​​
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Paper Excellence Group to Buy Resolute Forest Products
    Rose Baby Diaper Brand to Be Available in U.S.
    SWM, Neenah Complete Merger of Equals
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Enovis Buys Insight Medical Systems, a Surgical Guidance Firm
    No Revisions, Few Complications for Exactech's Total Ankle System
    SpineX Begins SCONE Clinical Trial
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Veridos Acquires Valid’s US Identity Solutions Business
    First Solar Completes Sale of Japan Project Development Platform to PAG Real Assets
    NREL Scientists Explore How to Make PV Even Greener

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login